Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-13.1
売上収益の対前年同期増減率（%）Wording
Conditional
How definitive the wording is.Results for this period
First quarter2022年4月1日〜2022年6月30日ConsolidatedIFRSNet Sales35,619¥ millionYear on year -13.1%Progress 26.6%
Operating profit10,276¥ millionYear on year -37.9%Progress 38.1%
Ordinary income10,514¥ millionYear on year -37.3%Progress 38.2%
Net income attributable to owners of the parent8,249¥ millionYear on year -34.5%Progress 38.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share122.48円
Financial position at period-end
Total assets219,684¥ million
of which net assets 185,227 ¥ millionEquity ratio 84.2%vs. prior year-end +2.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+3,872
Investment-1,566
Financials-4,289
Net change-1,983
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥58,915 million
Segment revenuePharmaceuticals Business ¥30,407 million (YoY -17.6%), Functional Foods Business ¥5,211 million (YoY +27.8%)
Segment profitPharmaceuticals Business ¥9,435 million, Functional Foods Business ¥68 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥134,000 million (YoY -2.5%)
Operating profit¥27,000 million (YoY -18.1%)
Ordinary income¥27,500 million (YoY -17.4%)
Net income¥21,500 million (YoY -14.0%)
Annual Dividend Forecast¥110 → ¥112（+1.8%）
Factors Behind Changes in Business Performance
優先審査バウチャーの売却一時金収入の反動、薬価改定、売上構成による売上原価率の上昇等。医薬品事業ではビルテプソ、ウプトラビ、海外売上に伴うロイヤリティ収入等が伸長し、機能食品事業ではプロテイン製剤、品質安定保存剤等の売上が増加。
Disclosure regarding the going concern assumption
該当事項なし（継続企業の前提に関する注記に「該当事項はありません」と記載）
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidation0 additions and 0 exclusions (no company names)
Depreciation and amortization¥1,221 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results Briefing有（機関投資家・証券アナリスト向けカンファレンスコール）
Issued Shares at Period-End70,251,484株
Treasury Shares at Period-End2,898,500株
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2022年4月1日〜2022年6月30日 |
| Net Sales | ¥35,619 million (YoY -13.1%) |
| Operating profit | ¥10,276 million (YoY -37.9%) |
| Ordinary income | ¥10,514 million (YoY -37.3%) |
| Profit attributable to owners of the parent | ¥8,249 million (YoY -34.5%) |
| Net income per share | 122.48円 |
| Equity ratio | End of the current fiscal period 84.2% / End of previous period 82.1% |
| Total assets | ¥219,684 million |
| Net assets | ¥185,227 million |
| Cash flows from operating activities | ¥3,872 million |
| Cash flows from investing activities | ¥-1,566 million |
| Cash flows from financing activities | ¥-4,289 million |
| Cash and cash equivalents at end of period | ¥58,915 million |
| Full-year earnings forecast | Net Sales ¥134,000 million (YoY -2.5%) / Operating profit ¥27,000 million (YoY -18.1%) / Ordinary income ¥27,500 million (YoY -17.4%) / Net income ¥21,500 million (YoY -14.0%) |
| Annual Dividend Forecast | ¥110 → ¥112（+1.8%） |
| Segment revenue | Pharmaceuticals Business ¥30,407 million (YoY -17.6%), Functional Foods Business ¥5,211 million (YoY +27.8%) |
| Segment profit | Pharmaceuticals Business ¥9,435 million, Functional Foods Business ¥68 million |
| Depreciation and amortization | ¥1,221 million |
| Disclosure regarding the going concern assumption | 該当事項なし（継続企業の前提に関する注記に「該当事項はありません」と記載） |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 0 additions and 0 exclusions (no company names) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | 有（機関投資家・証券アナリスト向けカンファレンスコール） |
| Issued Shares at Period-End | 70,251,484株 |
| Treasury Shares at Period-End | 2,898,500株 |
| Factors Behind Changes in Business Performance | 優先審査バウチャーの売却一時金収入の反動、薬価改定、売上構成による売上原価率の上昇等。医薬品事業ではビルテプソ、ウプトラビ、海外売上に伴うロイヤリティ収入等が伸長し、機能食品事業ではプロテイン製剤、品質安定保存剤等の売上が増加。 |
Items this document does not state (9)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.前年同期にあった優先審査バウチャーの売却一時金収入の反動により減収となり、減収と売上構成による売上原価率の上昇等により減益となった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.